Kenvue (NYSE:KVUE) Upgraded to “Hold” at Barclays

Kenvue (NYSE:KVUE) was upgraded by investment analysts at Barclays to a “hold” rating in a note issued to investors on Thursday,Zacks.com reports.

Several other equities analysts have also recently issued reports on KVUE. Royal Bank of Canada raised Kenvue from a “hold” rating to a “moderate buy” rating in a research note on Monday, December 9th. Bank of America lifted their target price on shares of Kenvue from $24.00 to $27.00 and gave the company a “buy” rating in a research note on Tuesday, October 22nd. Jefferies Financial Group began coverage on shares of Kenvue in a research note on Tuesday, September 24th. They issued a “buy” rating and a $27.00 price target for the company. Piper Sandler upped their target price on Kenvue from $20.00 to $21.00 and gave the stock a “neutral” rating in a report on Monday, September 23rd. Finally, JPMorgan Chase & Co. increased their target price on Kenvue from $24.00 to $25.00 and gave the stock an “overweight” rating in a research report on Friday, October 11th. One research analyst has rated the stock with a sell rating, eight have issued a hold rating and three have given a buy rating to the stock. According to MarketBeat, Kenvue presently has an average rating of “Hold” and a consensus price target of $22.64.

Kenvue Stock Performance

Shares of KVUE stock opened at $22.21 on Thursday. The company has a market capitalization of $42.58 billion, a P/E ratio of 40.38, a PEG ratio of 2.02 and a beta of 1.36. Kenvue has a fifty-two week low of $17.67 and a fifty-two week high of $24.46. The company has a debt-to-equity ratio of 0.66, a quick ratio of 0.69 and a current ratio of 1.00. The stock has a 50 day moving average price of $22.95 and a two-hundred day moving average price of $21.17.

Kenvue (NYSE:KVUE) last announced its quarterly earnings results on Thursday, November 7th. The company reported $0.28 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.27 by $0.01. The business had revenue of $3.90 billion for the quarter, compared to analyst estimates of $3.92 billion. Kenvue had a net margin of 6.88% and a return on equity of 21.43%. The company’s revenue was down .4% on a year-over-year basis. During the same quarter last year, the firm earned $0.31 EPS. Analysts expect that Kenvue will post 1.07 earnings per share for the current year.

Hedge Funds Weigh In On Kenvue

Several large investors have recently modified their holdings of the stock. Copley Financial Group Inc. bought a new stake in shares of Kenvue during the third quarter valued at approximately $569,000. Oddo BHF Asset Management Sas bought a new position in Kenvue in the 3rd quarter valued at approximately $1,570,000. Tidal Investments LLC boosted its stake in Kenvue by 9.9% during the 3rd quarter. Tidal Investments LLC now owns 131,128 shares of the company’s stock valued at $3,033,000 after purchasing an additional 11,849 shares during the last quarter. Wilmington Savings Fund Society FSB bought a new stake in shares of Kenvue in the 3rd quarter worth $1,057,000. Finally, Sanctuary Advisors LLC increased its holdings in shares of Kenvue by 166.3% in the 3rd quarter. Sanctuary Advisors LLC now owns 544,890 shares of the company’s stock worth $13,121,000 after purchasing an additional 340,266 shares in the last quarter. Hedge funds and other institutional investors own 97.64% of the company’s stock.

About Kenvue

Kenvue Inc operates as a consumer health company worldwide. The company operates through three segments: Self Care, Skin Health and Beauty, and Essential Health. The Self Care segment offers cough, cold and allergy, pain care, digestive health, smoking cessation, eye care, and other products under the Tylenol, Motrin, Benadryl, Nicorette, Zarbee's, ORSLTM, Rhinocort, Calpol, and Zyrtec brands.